上海医药(601607.SH)：利伐沙班片获得马来西亚药品注册证书

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory, received a drug registration certificate from the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for rivaroxaban tablets, which have been approved for market launch [1]. Group 1 - Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1]. - The drug is also indicated for the treatment and prevention of deep vein thrombosis (DVT) [1]. - Additionally, rivaroxaban is used for the treatment of pulmonary embolism (PE) and for the prevention of venous thromboembolism (VTE) in acutely ill patients [1].